Mevinolin; 6a-Methylcompactin; Monakolin K; MK-803, 6-alpha-Methylcompactin; BRN 3631989

Cancer cell line apoptotic inducer via HMG-CoA reductase mechanism. Statin compound. Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases. Causes cell cycle arrest in G1 and G2/M phases through modulation of proteasome in cancer cell lines. Smooth muscle cell proliferation inhibitor. Apoptosis inducer. Anticancer compound. Anti-adhesive, immunomodulatory and anti-inflammatory compound. Stimulates bone formation. Increases cellular resistance to anticancer agents such as doxorubicin and etoposide. Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Suppresses TNF-induced NF-kappaB activation. Modulates key cell signaling pathways, like Ras, MAPK and EGFR (modest).